問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Radiology

Division of Urology

Taichung Veterans General Hospital

Division of General Surgery

更新時間：2023-09-19

張延驊Chang, Yen-Hwa
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -3 個月

Recruiting Trial

46Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張延驊

List

107Cases

2017-02-01 - 2021-12-27

Phase III

Completed
A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN

  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    Atezolizumab

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

林永昌
Linkou Chang Gung Medical Foundation

2025-04-01 - 2027-12-31

Phase III

Active
A phase 3, two-part, randomized, open-label, modified trial comparing BMS-986365 with a trial-administered therapy (including Docetaxel or a second androgen receptor pathway inhibitor [ARPI]) in participants with metastatic castration-resistant prostate cancer (mCRPC) - rechARge

  • Condition/Disease

    Metastatic castration-resistant prostate cancer (mCRPC)

  • Test Drug

    BMS-986365 (CC-94676)

Participate Sites
4Sites

Recruiting4Sites

2024-10-01 - 2035-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2011-05-01 - 2014-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-01-04 - 2026-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2013-09-01 - 2024-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2024-11-01 - 2031-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-08-01 - 2035-08-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2029-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-12-30 - 2027-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB